Barinthus Biotherapeutics plc

NasdaqGM:BRNS 주식 보고서

시가총액: US$55.8m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Barinthus Biotherapeutics 관리

관리 기준 확인 2/4

Barinthus Biotherapeutics' CEO는 Bill Enright, Aug2019 에 임명되었습니다 의 임기는 4.83 년입니다. 총 연간 보상은 $ 1.81M, 33.7% 로 구성됩니다. 33.7% 급여 및 66.3% 보너스(회사 주식 및 옵션 포함). 는 $ 2.01M 가치에 해당하는 회사 주식의 3.19% 직접 소유합니다. 2.01M. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 4.6 년입니다.

주요 정보

Bill Enright

최고 경영자

US$1.8m

총 보상

CEO 급여 비율33.7%
CEO 임기4.9yrs
CEO 소유권3.2%
경영진 평균 재임 기간1.8yrs
이사회 평균 재임 기간4.7yrs

최근 관리 업데이트

Recent updates

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Apr 05
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Jul 07
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Nov 17
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Vaccitech promotes Gemma Brown to CFO

Sep 20

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15
Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13
Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

CEO 보상 분석

Bill Enright 의 보수는 Barinthus Biotherapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$2mUS$610k

-US$73m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$55m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$2mUS$569k

US$5m

Sep 30 2022n/an/a

US$11m

Jun 30 2022n/an/a

-US$1m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$3mUS$474k

-US$51m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$41m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$3mUS$350k

-US$18m

Dec 31 2019US$381kUS$128k

-US$21m

보상 대 시장: Bill 의 총 보상 ($USD 1.81M )은 US 시장( $USD 683.56K ).

보상과 수익: Bill 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

Bill Enright (62 yo)

4.9yrs

테뉴어

US$1,811,611

보상

Mr. William J. Enright, also known as Bill, MBA, is an Independent Director of Bullfrog AI Holdings, Inc. from February 14, 2023. He serves as Chief Executive Officer & Director of Barinthus Biotherapeutic...


리더십 팀

이름위치테뉴어보상소유권
William Enright
CEO & Director4.9yrsUS$1.81m3.19%
$ 1.8m
Nadege Pelletier
Chief Scientific Officer1.5yrsUS$1.71m0%
$ 0
Graham Griffiths
Chief Business Officer6.8yrsUS$731.06k0.27%
$ 149.0k
Sarah Gilbert
Co-Founderno dataUS$48.98k데이터 없음
Adrian Hill
Co-Founder & Scientific Advisorno dataUS$61.61k데이터 없음
Gemma Brown
CFO & Company Secretary1.8yrs데이터 없음데이터 없음
Elizabeth Eagling-Vose
Head of Clinical Operationsno data데이터 없음데이터 없음
Bernie McDonald
Head of IPno data데이터 없음데이터 없음
Geoffrey Lynn
Senior Vice President of Synthetic Immunotherapiesno data데이터 없음데이터 없음
Leon Hooftman
Chief Medical Officerless than a year데이터 없음데이터 없음

1.8yrs

평균 재임 기간

44.5yo

평균 연령

경험이 풍부한 관리: BRNS 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.


이사회 구성원

이름위치테뉴어보상소유권
William Enright
CEO & Director4.9yrsUS$1.81m3.19%
$ 1.8m
Karen Dawes
Independent Non-Executive Director3.4yrsUS$81.69k0.0044%
$ 2.4k
Drew Pardoll
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Anne Phillips
Independent Non-Executive Director3.4yrsUS$81.06k0.0077%
$ 4.3k
Robin Wright
Independent Chairman of the Board5.9yrsUS$117.13k0.12%
$ 69.0k
Pierre Armand Morgon
Independent Non-Executive Director6.5yrsUS$85.42k0.027%
$ 15.0k
Jerome Kim
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Alex Hammacher
Non-Executive Director4.5yrsUS$71.11k0.0077%
$ 4.3k
Steve Dewhurst
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Benoit den Eynde
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Patricia Fast
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Mark Tuthill
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

4.7yrs

평균 재임 기간

61.5yo

평균 연령

경험이 풍부한 이사회: BRNS 의 이사회경험(평균 재직 기간 4.6 년)으로 간주됩니다.